RxDoctor Payments Data

Matthew Fulton

Surgery · Cincinnati, OHNPI 1255561775

Payments from drug & device makers

$15,284in general payments, 2019–2025

Across 772 payments — averaging $19.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$2K
  • Johnson & Johnson$1K
  • Bayer$1K
  • Calyxo, Inc.$867
  • Merck$749
  • Coloplast$726
  • plus $9K from 50 others

What the payments were for

  • Travel & lodging$2201%
  • Food & beverage$14,44394%
  • Education$6204%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,284 in reported general payments places this provider in the 85th percentile of 988 surgery providers in Ohio.

See all surgery providers in Ohio

Medicare billing

Part B allowed, 2024
$273,324
Medicare patients
675
Services billed
5,366

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix106$282,833
Abiraterone Acetate51$222,104
NubeqaDarolutamide13$156,068
MyrbetriqMirabegron179$107,503
GemtesaVibegron108$76,969
Tamsulosin Hcl1,146$11,052
Solifenacin Succinate128$4,782
Finasteride483$4,699
Potassium Citrate ErPotassium Citrate24$3,848
Methenamine Hippurate54$3,113
Fesoterodine Fumarate ErFesoterodine Fumarate27$3,023
Alfuzosin Hcl ErAlfuzosin Hcl77$1,254
Testosterone Cypionate39$999
Estradiol15$979
Cephalexin98$967

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$476$359,802214 claims
BayerNubeqa$1,013$156,06813 claims
Astellas Pharma US IncMyrbetriq$1,727$107,503179 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 988 surgery providers in Ohio.

Other surgery in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →